On this page
A 510(k) is a premarket submission to the FDA demonstrating that a device is substantially equivalent to an already-cleared device, allowing faster market access without independent proof of safety and efficacy. The FDA issues a clearance letter within 90 days if equivalence is established.
- A 510(k) clearance certifies substantial equivalence to a predicate device, not independent safety or efficacy.
- The FDA review process follows a 15-60-90 day timeline: acceptance review within 15 days, substantive review within 60 days, and final decision within 90 days.
- Substantial equivalence requires matching intended use and key performance characteristics, but not necessarily identical mechanisms or materials.
- 510(k) is faster and less expensive than PMA or De Novo pathways, costing $50,000 to $250,000 plus FDA user fees.
- Post-market surveillance continues after clearance; devices can be recalled or restricted if adverse events emerge.
When a medical device company files a regulatory submission with the FDA, the pathway it chooses determines how much evidence it must gather, how long the review will take, and what the agency will evaluate. The 510(k) is the most common of these pathways, and it works differently than many people assume.
A 510(k) is a premarket submission made to demonstrate that a device is substantially equivalent to a legally marketed device already cleared by the FDA. It is not an approval of the device's safety and efficacy in isolation. Instead, it is a finding that the new device matches an existing one in intended use and key performance characteristics. This distinction shapes everything about how the pathway functions: what companies must research, how long the process takes, and what clearance actually guarantees.
What a 510(k) clearance actually is
A 510(k) is a specific regulatory submission pathway, not a general approval category. The term refers to the section of the Code of Federal Regulations that governs it: 21 CFR Part 807 Subpart E. Before a medical device can be marketed in the United States, the manufacturer must receive a letter from the FDA finding the device substantially equivalent to a legally marketed predicate device. That letter is the clearance. It authorizes marketing but does not certify that the device is safe and effective in an absolute sense. Instead, it certifies that the device has the same intended use as the predicate and meets statutory criteria for substantial equivalence. This is a narrower claim than independent proof of safety and efficacy, and it is the reason the 510(k) pathway exists: to allow faster market access for devices that are not fundamentally novel.
How the 510(k) pathway works
The 510(k) process moves through distinct phases, each with its own decision point. A company begins by selecting a predicate device, then assembles evidence that its own device is substantially equivalent, then submits to the FDA for review. Understanding each step clarifies what applicants must do and what the FDA evaluates.
The substantial equivalence requirement
Substantial equivalence is the core test. A device meets it when it has the same intended use as the predicate device and meets the statutory criteria the FDA applies. Intended use is specific: it describes the disease or condition the device is meant to treat or diagnose, the population it is meant to treat, and the role it plays in clinical care. Two devices with the same intended use but different mechanisms of action, materials, or performance characteristics may still be substantially equivalent if the differences do not affect safety or efficacy. The applicant must make and support this claim with evidence, typically through bench testing, animal studies, or clinical data depending on the device type and the predicate's history. The FDA does not require the applicant to prove the device works; it requires the applicant to demonstrate that it works as well as the predicate does.
Predicate device selection
The applicant must identify a similar legally marketed U.S. device to serve as the predicate. This choice is consequential. The predicate defines the bar for equivalence. If the predicate is a simple device with minimal regulatory history, the equivalence claim may be straightforward. If the predicate is complex or controversial, the comparison becomes harder. Applicants sometimes select multiple predicates to strengthen their case, comparing their device to more than one cleared device. The predicate must already be legally marketed in the United States; it cannot be a device cleared in another country or one still under FDA review. Once a device is cleared through 510(k), it can itself become a predicate for future submissions, which creates a chain of equivalence claims over time.
Submission review and FDA decision
After submission, the FDA follows a structured review timeline. The agency first checks whether the submission is complete and properly formatted. If it is, the applicant receives acceptance within 15 calendar days. If not, the FDA issues a deficiency letter and the clock resets. Once accepted, the FDA conducts substantive review, evaluating the equivalence claim and the supporting data. The agency expects to issue a substantive review decision within 60 calendar days. The final decision comes within 90 calendar days. If the FDA finds substantial equivalence, it issues a letter stating that the device can be marketed. If it does not, it issues a not substantially equivalent (NSE) letter, and the applicant must either revise the submission, select a different predicate, or pursue an alternative pathway such as De Novo or PMA.
Why 510(k) clearance matters for device companies
The 510(k) pathway has direct business consequences. It is faster and less expensive than the alternatives. The 90-day review timeline allows companies to plan product launches with reasonable certainty about timing. The cost of a 510(k) submission, including FDA user fees and consultant work, typically ranges from $50,000 to $250,000 depending on device complexity and testing requirements. The FDA user fee alone is $26,067 for a standard submission or $6,517 for a small business. By contrast, the PMA pathway requires independent clinical trial data and takes substantially longer. For companies with limited capital, the speed and cost advantage of 510(k) can determine whether a product reaches market at all. For established manufacturers, 510(k) is the default pathway for incremental improvements to existing products. The availability of a suitable predicate device often shapes product strategy: if a company can design a device that is substantially equivalent to an existing cleared device, it can move faster than if it must prove the device is novel.
510(k) clearance versus other FDA pathways
The FDA offers three main premarket pathways for medical devices, and they differ fundamentally in what they require and how long they take. Understanding these differences clarifies why 510(k) is common and when companies use the others. The 510(k) pathway requires demonstration of substantial equivalence to a predicate device. The PMA (Premarket Approval) pathway requires independent clinical data proving safety and efficacy. PMA review takes substantially longer: under current FDA goals, the average total time to decision is approximately 285 days in FY 2025-2027. The De Novo pathway is for devices that are new in kind, with no suitable predicate. De Novo provides a way to establish a new device classification as class I or class II. Once a device is cleared through De Novo, it can become a predicate for future 510(k) submissions. A company chooses 510(k) when a predicate exists and equivalence can be demonstrated. It chooses PMA when the device is truly novel or when the predicate's regulatory history is weak. It chooses De Novo when the device is new and no predicate exists, accepting a longer review in exchange for establishing a new category.
Common misreadings of 510(k) clearance
The 510(k) pathway is sometimes misunderstood regarding its rigor and scope. Clearance means the device meets a specific, defined standard: substantial equivalence to a predicate. It does not mean the device is automatically safe or effective, and it does not exempt the device from post-market oversight.
510(k) is not FDA approval of safety and efficacy
The 510(k) pathway relies on comparison to a predicate device rather than independent FDA testing. The agency evaluates whether the device is substantially equivalent to a predicate. If the predicate was poorly studied or has a history of adverse events, the 510(k) device inherits that uncertainty. The applicant must demonstrate equivalence, but equivalence is not the same as proof of safety. It is a finding that the device matches the predicate in intended use and key characteristics. If the predicate itself was cleared based on limited data, the 510(k) device may also have limited safety data. This is not a flaw in the pathway; it is how the pathway is designed. The 510(k) pathway is used for devices that are substantially equivalent to legally marketed devices. The rigor of 510(k) review depends on the comparison to the predicate device.
Clearance does not mean the device is risk-free
A 510(k) clearance authorizes marketing of the device. Devices remain subject to post-market surveillance after clearance. The FDA can require additional studies, impose restrictions on use, or issue recalls if adverse events emerge. A device cleared through 510(k) can be removed from the market or restricted to specific uses if post-market data shows unexpected risks. Clearance means the device met the equivalence standard at the time of review, based on the evidence submitted. It does not mean future use will reveal no problems.
How 510(k) clearance connects to device market analysis
Understanding the 510(k) pathway helps readers interpret device company filings and assess competitive positioning. When a company announces that a device has received 510(k) clearance, the announcement tells you that the device is substantially equivalent to an existing cleared device and can now be marketed. It does not tell you whether the device is innovative, whether it will succeed commercially, or whether it has clinical advantages over competitors. To assess those questions, you need additional information: what predicate was used, how the device differs from that predicate, and what clinical evidence exists. A company filing often mentions the predicate device in the regulatory section. Comparing the new device to the predicate gives insight into the company's strategy. If the predicate is an older device with limited functionality, the new device may represent meaningful innovation even though it is substantially equivalent. If the predicate is recent and feature-rich, the new device may be a minor variation. The 510(k) pathway also shapes timelines. If a company has identified a suitable predicate, it can plan for market entry within roughly 90 days of submission. If no predicate exists, the company must pursue De Novo or PMA, which take longer. Reading a company's regulatory strategy and predicate choices reveals how management views the device's position in the market and how quickly it expects to compete.
Do this automatically
A company assembling a 510(k) submission must coordinate predicate device selection, evidence gathering, formatting verification, and FDA timeline tracking across multiple internal teams and external consultants, with review cycles often spanning months and involving repeated document revisions. These coordination tasks, selecting the right predicate, organizing substantial equivalence data, managing submission completeness checks, and tracking regulatory timelines, can be systematized and accelerated through software. Healthcare research runs this kind of analysis end to end and cites every figure back to its original source, across as many subjects as you need, with Mimir attaching a citation to every figure. It will not predict a trial's outcome or advise on anyone's treatment. Those decisions stay with clinicians and regulators, and deliberately so. Every plan includes it, including the free one.
Start your first report and run it on something you already know well.
This article is general information about healthcare and life-sciences topics. It is not medical advice, diagnosis, or treatment guidance, and it is not a substitute for a qualified professional. Any treatment decision should be discussed with a clinician.
